A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)

Degirmencioglu S., Tanriverdi O., Menekse S., Dogan M., Hacioglu B., Oktay E., ...More

JOURNAL OF BUON, vol.24, no.1, pp.242-248, 2019 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 1
  • Publication Date: 2019
  • Journal Name: JOURNAL OF BUON
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.242-248


Purpose: To compare the efficacy and adverse effect profiles of the first-line treatment of patients with KRAS wild type metastatic colorectal cancer (CRC) in Turkey who were treated based on regimens including bevacizumab, cetuximab and panitumumab.